Polaryx Therapeutics Inc. Common Stock
PLYX | NASDAQ
$1.73
-$0.02 (-1.14%)
Nov 2, 2026, 1:11 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 |
|---|---|---|---|
Revenue | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a |
Operating Income | -7.82M | -4.35M | -3.78M |
Interest Income | n/a | n/a | n/a |
Pretax Income | -8.99M | -30.36M | -3.78M |
Net Income | -8.99M | -30.36M | -3.78M |
Selling & General & Admin | 1.56M | 1.54M | 1.01M |
Research & Development | 6.27M | 2.81M | 2.77M |
Other Expenses | n/a | n/a | n/a |
Operating Expenses | 7.82M | 4.35M | 3.78M |
Interest Expense | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a |
Cost & Expenses | 7.82M | 4.35M | 3.78M |
Income Tax Expense | n/a | n/a | n/a |
Shares Outstanding (Basic) | 47.34M | 189.37M | 189.37M |
Shares Outstanding (Diluted) | 47.34M | 189.37M | 189.37M |
EPS (Basic) | -0.19 | -0.16 | -0.02 |
EPS (Diluted) | -0.19 | -0.16 | -0.02 |
EBITDA | -8.99M | -30.36M | -3.78M |
EBIT | -8.99M | -30.36M | -3.78M |
Depreciation & Amortization | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove PLYX